New vulnerability found in lung squamous cancer may facilitate drug targeting

September 25, 2020

CHAPEL HILL, N.C.--New cancer research by scientists at UNC Lineberger Comprehensive Cancer Center, and colleagues, shows the potential for targeting a specific circular RNA, known as CDR1as, to attack lung squamous cell cancer. Lung squamous cell cancers comprise up to 30% of all lung cancers and are responsible for about 70,000 new cases and approximately 40,000 deaths each year in the U.S.

The results from this study are published in Cancer Research, a journal of the American Association for Cancer Research.

"Cancer is revealing, at a rapid pace, that it has many more vulnerabilities than we previously believed, including the one we've elucidated, which undoubtedly means better treatment options ahead," said study senior author UNC Lineberger's Chad V. Pecot, MD, an associate professor at the UNC School of Medicine. "I'm very hopeful, based on our work and much of what is being done in the field of drug development, that many new medicines are on the horizon."

For decades, scientists dismissed RNAs that joined ends to form circles as splicing errors. Research by former UNC Lineberger director Ned Sharpless, MD, and current director of the National Cancer Institute, among others, revealed that these RNAs are highly abundant and compromise a new class of RNA called circRNAs.

Many circRNAs, including the one in this study (CDR1as), are thought to work by targeting and inhibiting other RNAs. However, after many years of investigation, the researchers discovered that one of the keys to how CDR1as works was through an unstudied protein called CDR1. With the help of several collaborators, they found the answer came by looking at Golgi trafficking.

Golgi bodies in a cell ensure that the proteins a cell produces get to where they need to go and exert their designed function. For cancer cells, this means that Golgi must reposition themselves so that cells can metastasize, or spread, to other parts of the body. Most cellular behavior is ultimately regulated by proteins, so if Golgi trafficking is altered, this can be hugely consequential to what happens in the cell. This new research uncovers some of the first connections of circRNAs with Golgi trafficking.

"We found that CDR1as plays a large role in driving metastasis in lung squamous cancer," said Pecot. "However, because nothing was really known about CDR1, the protein regulated by CDR1as, our journey was just beginning. We eventually determined that CDR1 in part operates by increasing Golgi trafficking, which we found to be critical to its role in helping cancer spread."

The researchers say they will continue to explore the intricate biology of both CDR1as and CDR1. According to Pecot, these both represent very enticing drug targets because they are usually not turned on in the rest of the body. So blocking them would be destructive to cancer cells but should not cause much toxicity to the rest of the body.

"The study of CDR1as is only just beginning, and our research highlights a new mechanism for circRNA function that has implications beyond cancer biology," said study first author Emily B. Harrison, PhD, postdoctoral research associate at UNC Lineberger and UNC Eshelman School of Pharmacy. "This has been a huge team effort across UNC, including many Lineberger members as well as researchers across several departments. It truly exemplifies a successful team effort."
-end-


UNC Lineberger Comprehensive Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.